rs10842703 - SSPN-AS1

Magnitude 2.2 · 4 studies on file

Reported associations

  • Comprehensive genetic study of the insulin resistance marker TG:HDL-C in the UK Biobank. - Nature genetics (2024) · Oliveri A, Rebernick RJ, Kuppa A, Pant A, Chen Y, Du X, Cushing KC, Bell HN, Raut C, Prabhu P, Chen VL, Halligan BD, Speliotes EK · PubMed 38200128

    Insulin resistance (IR) is a well-established risk factor for metabolic disease. The ratio of triglycerides to high-density lipoprotein cholesterol (TG:HDL-C) is a surrogate marker of IR. We conducted a genome-wide association study of the TG:HDL-C ratio in 402,398 Europeans within the UK Biobank. We identified 369 independent SNPs, of which 114 had a false discovery rate-adjusted P value < 0.05 in other genome-wide studies of IR making them high-confidence IR-associated loci. Seventy-two of these 114 loci have not been previously associated with IR. These 114 loci cluster into five groups upon phenome-wide analysis and are enriched for candidate genes important in insulin signaling, adipocyte physiology and protein metabolism. We created a polygenic-risk score from the high-confidence

  • Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis - Unknown journal (n.d.) · Unknown authors · PubMed 38632349

    ABSTRACT: We report a multi-ancestry genome-wide association study on liver cirrhosis and its associated endophenotypes, alanine aminotransferase (ALT) and γ-glutamyl transferase. Using data from 12 cohorts, including 18,265 cases with cirrhosis, 1,782,047 controls, up to 1 million individuals with liver function tests and a validation cohort of 21,689 cases and 617,729 controls, we identify and validate 14 risk associations for cirrhosis. Many variants are located near genes involved in hepatic lipid metabolism. One of these, PNPLA3 p.Ile148Met, interacts with alcohol intake, obesity and diabetes on the risk of cirrhosis and hepatocellular carcinoma (HCC). We develop a polygenic risk score that associates with the progression from cirrhosis to HCC. By focusing on prioritized genes from c

  • The power of genetic diversity in genome-wide association studies of lipids - Unknown journal (n.d.) · Unknown authors · PubMed 34887591

    ABSTRACT: Elevated blood lipid levels are heritable risk factors of cardiovascular disease with varying prevalence worldwide due to differing dietary patterns and medication use. Despite advances in prevention and treatment, particularly through the lowering of low-density lipoprotein cholesterol levels, heart disease remains the leading cause of death worldwide. Genome-wide association studies (GWAS) of blood lipid levels have led to important biological and clinical insights, as well as new drug targets, for cardiovascular disease. However, most previous GWAS have been conducted in European ancestry populations and may have missed genetic variants contributing to lipid level variation in other ancestry groups due to differences in allele frequencies, effect sizes, and linkage-disequilibr

  • Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis - Unknown journal (n.d.) · Unknown authors · PubMed 32203549

    ABSTRACT: Background Circulating lipoprotein lipids cause coronary heart disease (CHD). However, the precise way in which one or more lipoprotein lipid-related entities account for this relationship remains unclear. Using genetic instruments for lipoprotein lipid traits implemented through multivariable Mendelian randomisation (MR), we sought to compare their causal roles in the aetiology of CHD. Methods and findings We conducted a genome-wide association study (GWAS) of circulating non-fasted lipoprotein lipid traits in the UK Biobank (UKBB) for low-density lipoprotein (LDL) cholesterol, triglycerides, and apolipoprotein B to identify lipid-associated single nucleotide polymorphisms (SNPs). Using data from CARDIoGRAMplusC4D for CHD (consisting of 60,801 cases and 123,504 controls), we per


Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Bloodwork

  • Lipid panel (triglycerides, HDL, LDL, total cholesterol) Moderate

    Elevated triglyceride/HDL ratio is a cardiovascular risk marker; monitoring tracks intervention response

    Check lipid panel every 6-12 months, or more frequently if abnormal

    • GWAS_CATALOG:38200128

Diet

  • Omega-3 fatty acids (fish or supplements) Moderate

    Omega-3 fatty acids reduce triglycerides and support HDL cholesterol

    2-3 servings fatty fish weekly, or 1-2g EPA+DHA supplement daily

    • GWAS_CATALOG:38200128
  • Sugar-sweetened beverages Moderate

    Added sugars raise triglycerides and worsen triglyceride/HDL ratio

    Eliminate or limit to <=1 per week

    • GWAS_CATALOG:38200128
  • Whole grains instead of refined grains Moderate

    Whole grains reduce triglycerides and improve triglyceride/HDL ratio

    Replace half of refined grains with whole grains daily

    • GWAS_CATALOG:38200128

Discuss with your doctor

  • Lipid management strategy given genetic predisposition Moderate

    rs10842703 is associated with elevated triglyceride/HDL ratio; individualized management may involve medication

    Review baseline lipid panel and family history, discuss prevention strategy

    • GWAS_CATALOG:38200128

Exercise

  • Aerobic exercise Moderate

    Regular aerobic activity lowers triglycerides and raises HDL cholesterol

    150 minutes moderate-intensity aerobic exercise weekly

    • GWAS_CATALOG:38200128